Xortx Therapeutics Inc. 6-K Filing
Ticker: XRTX · Form: 6-K · Filed: Mar 27, 2026 · CIK: 0001729214
| Field | Detail |
|---|---|
| Company | Xortx Therapeutics Inc. (XRTX) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2026 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Xortx Therapeutics Inc. (ticker: XRTX) to the SEC on Mar 27, 2026.
How long is this filing?
Xortx Therapeutics Inc.'s 6-K filing is 1 pages with approximately 133 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 133 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2026-03-27 06:00:11
Filing Documents
- f6k_032626.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 13KB
- 0001171843-26-001954.txt ( ) — 20KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: March 26, 2026 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Report of Voting Results